SCHEMBL13747692

SCHEMBL13747692

CCC(=O)c1cc(Cl)c(NS(C)(=O)=O)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.43
TSHR P16473 1/20 0.41
EPHX2 P34913 7/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
PPARG P37231 2/20 0.36
HPGD P15428 1/20 0.36
RECQL P46063 1/20 0.36
NR1H4 Q96RI1 5/20 0.36
CYP3A4 P08684 1/20 0.36
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SCN9A Q15858 1/20 0.35
BRD4 O60885 1/20 0.34
BAZ2B Q9UIF8 1/20 0.34
BAZ2A Q9UIF9 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13869046 0.81 CA2 (0.41) PPARATSHREPHX2PPARGNR1H4
SCHEMBL3532868 0.81 TTR (0.48) TSHR
SCHEMBL13748165 0.80 ADRB3 (0.44) PPARAEPHX2GRIN1GRIN2BHPGD
SCHEMBL13719497 0.77 EPHX2 (0.40) EPHX2GRIN1GRIN2BPPARGNR1H4
SCHEMBL14038485 0.76 ALDH1A1 (0.47) TSHREPHX2GRIN1GRIN2BHPGD
SCHEMBL14960121 0.74 ACLY (0.44) TSHRHPGDALDH1A1SMN1; SMN2PTGS2
SCHEMBL28277550 0.74 PPARA (0.47) PPARATSHRPPARGHPGDCYP3A4
SCHEMBL23979141 0.72 CYP3A4 (0.47) PPARATSHRPPARGCYP3A4SMN1; SMN2
SCHEMBL13996133 0.72 FFAR4 (0.42) TSHRHPGDALDH1A1
SCHEMBL6808373 0.72 TTR (0.56) PPARATSHRPPARGRECQLCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569579-B2 for inhibition of HIV replication and treatment of acquired immune deficiency syndrome SMITHKLINE BEECHAM CORPORATION (US) 2009-08-04 US disclosed
US-7452992-B2 inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS); 1-((1R,5S)-8-{2-[3-(2,2-dimethylpropanoyl)-6-phenyl-1,3-oxazinan-6-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole SMITHKLINE BEECHAM CORPORATION (US) 2008-11-18 US disclosed